Global Imatinib Drugs Market Size, Share and Trends Analysis Report, By Application (Philadelphia Positive Chronic Myeloid Leukemia, Hyper-Eosinophilic Syndrome (HES), Myelodysplastic Syndrome (MDS), Myeloproliferative Diseases (MPD), Gastrointestinal Stromal Tumors (GIST), and Others) Forecast (2022-2028)

The global imatinib drugs market is expected to witness moderate growth registering 7.2% CAGR during the forecast period (2022-2028). An imatinib drug is generally used to treat acute lymphoblastic leukemia in adults and children that is Philadelphia chromosome-positive. The global imatinib drugs market is growing due to the rising prevalence of cancer as well as growing demand for target drug therapy. According to the Leukemia and Lymphoma Society, every three minutes, one person in the US alone is diagnosed with Leukemia or myeloma. Around 186,400 people were diagnosed with Leukemia and myeloma in the US in 2021. Additionally, the improved healthcare infrastructure in the emerging economic countries as well as a huge investment in research and development by the key manufacturer for the advancement in the treatment and drugs is also driving the global imatinib drugs market growth. The global imatinib drugs market is segmented based on application. The Philadelphia positive chronic myeloid leukemia segment is anticipated to hold the major share in the market due to the high prevalence of leukemia patients globally as compared to other types of disorders. The GSIT segment is expected to grow fastest during the forecast period as imatinib is been used as the first-line therapy for GIST.

The market player is also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and launches, to stay competitive in the market. For instance-
In October 2021, Tenax Therapeutics received clearance from the US Food and Drug Administration (FDA) for the investigational new drug application of Imatinib in pulmonary arterial hypertension.
In August 2021, Aerami Therapeutics received US FDA approval of orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension.
In August 2021, World Health Organization announced the next phase of the Solidarity PLUS trial by enrolling COVID-19 patients with promising drugs artesunate, imatinib, and infliximab which will be used for reducing the risk of death in hospitalized COVID-19 patients.
In July 2019, Lupin launched Imatinib Mesylate Tablets, 100 mg (base) and 400mg (base).

Market Coverage
The market number available for – 2022-2028
Base year- 2021
Forecast period- 2022-2028

Segment Covered-
By Application

Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

Competitive Landscape-
Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Novartis AG, Mylan N.V., Dr. Reddy’s Laboratories Ltd., and Apotex Inc., among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Imatinib Drugs Market Report by Segment
By Application
Philadelphia Positive Chronic Myeloid Leukemia
Hyper-Eosinophilic Syndrome (HES)
Myelodysplastic Syndrome (MDS)
Myeloproliferative Diseases (MPD)
Gastrointestinal Stromal Tumor (GIST)
Others